Inovio Pharmaceuticals, Inc.

INO Details
 
Received Order from World Health Organization: Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company focused on designing DNA medicines to treat/cure diseases associated with HPV, cancer, and infectious diseases. Recently, the company informed that it has received an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19. The company further informed that with its modern DNA medicines platform, the company designed its DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.

Q3FY19 Operational Highlights for the Period ended 30 September 2019: INO declared its quarterly results, wherein the company reported total revenue of $866,863, down from $2,000,868 on the previous corresponding period, due to a reduction in manufacturing services under the AstraZeneca collaboration. Research and development expenses for the quarter stood at $19.1 million, down from $21.9 million, due to reductions in both employee compensation expense and drug manufacturing expense. General and administrative expenses declined to $5.7 million from $6.8 million in Q3FY18, on account of decreases in employee compensation, depreciation expense and legal expenses. However, the decline was partially offset by personnel-related restructuring charge related to one-time employee termination costs incurred during the quarter. The company reported a net loss of $23,536,452, indicating an improvement from $25,015,672 in the previous corresponding period.


Q3FY19 Income Statement Highlights (Source: Company Reports)

Balance Sheet Update: As on 30^th September 2019, the company reported total current assets of $98,812,541, which includes cash and cash equivalents of $15,853,236 and short-term investments of $77,945,753. Fixed assets were reported at $13,516,389, while the business reported goodwill and operating lease right-of-use assets of $10,513,371 and $14,002,860, respectively. The company reported total assets and total stockholders’ equity of $151,533,430 and $36,118,732, respectively.

Stock Recommendation:The stock of INO closed at $14.09 with a market capitalization of ~$1.43 billion. The stock made a 52-week low and high of $10.68 and $16.00 and is currently trading at the upper band of its 52-week trading range.  The stock has generated excellent returns of ~490.77% and ~561.50% in the last three months and six months, respectively. In the last one week, the stock has delivered a positive return of 229.20%.With its novel SynCon^® immunotherapy design, the business has shown the ability to help break the immune system’s tolerance of cancerous cells. With the SynCon^® product design approach, the company intended to facilitate cross-strain protection against known and new unmatched strains of pathogens, such as influenza. Recently, the business received orders from WHO for the manufacturing of medicines used for COVID-19.The company’s corporate strategy is to develop, protect and utilize its differentiated immunotherapy platform. Going forward, the company seeks to progress and validate an array of HPV related diseases, as well as cancer and infectious disease immunotherapy and vaccine products. Considering the aforesaid facts, current trading levels and business prospects, we have a wait and watch stance on the stock at the closing price of $14.09, up 43.78% as on 6^th March 2020.

 
INO Daily Technical Chart (Source: Thomson Reuters)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.